Skip to content

US · GEHC · MEDICAL - HEALTHCARE INFORMATION SERVICES

GE HealthCare Technologies Inc. (GEHC) intrinsic value and stock valuation

$80.64as of 2026-11-21 · Mkt cap 32.42B

Data updated · price as of 2026-11-21

Fairly valuedIC value is within 20% of the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

GE HealthCare Technologies Inc. DCF and intrinsic value

InvestorsCraft values GEHC with the Chepakovich two-stage DCF model — currently rated fairly valued. How the model works · Run your own DCF prefilled from GEHC’s statements →

GE HealthCare Technologies Inc. Graham Number

Graham Number: $48.83d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Medical - Healthcare Information Services Chicago, IL 60661 gehealthcare.com

How the business is doing

Fiscal 2019–2025, USD

Revenue
$20.6B+3.7% 5y CAGRd
20192025
Net income
$2.08B-31.5% 5y CAGRd
20192025
Free cash flow
$1.51B+1.1% 5y CAGRd
20192025
Total equity
$10.6B-6.7% 5y CAGRd
20202025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2019–2025, USD
20252024202320222021
Revenue$20.6B$19.7B$19.6B$18.3B$17.6B
Operating income$2.76B$2.63B$2.44B$2.52B$2.8B
Net income$2.08B$1.99B$1.57B$1.92B$2.25B
EPSd$4.53M$4.34M$3.42M$4.22M$4.94M
Operating cash flow$1.99B$1.95B$2.1B$2.11B$1.61B
Capital expenditure-$-482M-$-401M-$-387M-$-310M-$-248M
Free cash flow$1.51B$1.55B$1.71B$1.8B$1.36B
Total assets$36.9B$33.1B$32.5B$27.5B$26.3B
Total debt$10B$9.38B$9.86B$8.64B$437M
Net debt$5.49B$6.49B$7.36B$7.19B-$-119M
Total equity$10.6B$8.65B$7.31B$9.59B$16.9B
Cash and short-term investments$4.51B$2.89B$2.5B$1.45B$556M
Income statement
20252024202320222021
Revenue$20.6B$19.7B$19.6B$18.3B$17.6B
Cost of revenue$12.4B$11.5B$11.6B$11.2B$10.4B
Gross profit$8.25B$8.21B$7.92B$7.18B$7.17B
Research and development expenses$1.26B$1.31B$1.21B$1.03B$816M
Selling, general and administrative expenses$4.23B$4.27B$4.28B$3.63B$3.56B
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$5.49B$5.58B$5.49B$4.66B$4.38B
Cost and expenses$17.9B$17B$17.1B$15.8B$14.8B
Interest income$0.00$0.00$26M$0.00$34M
Interest expense$450M$505M$542M$86M$40M
Depreciation and amortization$578M$580M$610M$633M$625M
Ebitda$3.79B$3.67B$3.51B$3.17B$3.54B
Operating income$2.76B$2.63B$2.44B$2.52B$2.8B
Total other income/expenses, net$6M-$-44M-$-74M-$-10M$80M
Income before tax$2.77B$2.58B$2.36B$2.51B$2.88B
Income tax expense$614M$531M$743M$563M$600M
Net income$2.08B$1.99B$1.57B$1.92B$2.25B
Weighted average shares outstanding$456.5M$456M$455M$453.9M$454.7M
Weighted average diluted shares outstanding$460.3M$459M$458M$453.9M$454.7M
Balance sheet
20252024202320222021
Cash and short-term investments$4.51B$2.89B$2.5B$1.45B$556M
Net receivables$3.96B$4.38B$4.32B$3.99B$3.79B
Inventory$2.23B$1.94B$1.96B$2.16B$1.95B
Total current assets$10.7B$9.52B$9.01B$7.82B$6.54B
Property, plant and equipment, net$3.09B$2.55B$2.5B$2.31B$2.24B
Goodwill and intangible assets$14.6B$14.2B$14.2B$14.3B$14.7B
Long-term investments$0.00$804M$733M$663M$665M
Total non-current assets$22.2B$23.6B$23.4B$19.7B$19.8B
Total assets$36.9B$33.1B$32.5B$27.5B$26.3B
Accounts payable$3.25B$3.02B$2.95B$3.09B$2.73B
Short-term debt$508M$1.62B$1.12B$119M$110M
Deferred revenue$0.00$1.94B$1.92B$1.9B$1.86B
Total current liabilities$9.11B$9.55B$8.98B$7.19B$6.76B
Long-term debt$9.5B$7.76B$8.75B$8.52B$327M
Deferred revenue, non-current$0.00$686M$705M$630M$632M
Total non-current liabilities$17.2B$14.9B$16.2B$10.8B$2.65B
Capital lease obligations$0.00$425M$311M$282M$296M
Total liabilities$26.3B$24.4B$25.1B$17.9B$9.41B
Common stock$5M$5M$5M$11.2B$17.7B
Retained earnings$5.28B$3.26B$1.33B$0.00$0.00
Accumulated other comprehensive income (loss)-$-1.39B-$-1.38B-$-691M-$-1.88B-$-1.04B
Total equity$10.6B$8.65B$7.31B$9.59B$16.9B
Total investments$0.00$804M$733M$663M$665M
Total debt$10B$9.38B$9.86B$8.64B$437M
Net debt$5.49B$6.49B$7.36B$7.19B-$-119M
Cash flow statement
20252024202320222021
Net income$2.15B$2.05B$1.62B$1.95B$2.28B
Depreciation and amortization$578M$580M$610M$633M$625M
Stock-based compensation$130M$125M$114M$67M$76M
Change in working capital-$-357M-$-59M$22M-$-293M-$-1.37B
Accounts receivable-$-216M-$-150M-$-171M-$-440M-$-1.16B
Inventory-$-142M-$-81M$111M-$-402M-$-435M
Accounts payable$90M$126M-$-13M$481M$263M
Net cash provided by operating activities$1.99B$1.95B$2.1B$2.11B$1.61B
Investments in property, plant and equipment-$-482M-$-401M-$-387M-$-310M-$-248M
Acquisitions, net$0.00-$-313M-$-147M$0.00-$-1.48B
Net cash used for investing activities-$-1.05B-$-914M-$-558M-$-398M-$-1.76B
Common stock issued$37M$33M$0.00$0.00$0.00
Common stock repurchased-$-200M$0.00$0.00$0.00$0.00
Dividends paid-$-64M-$-55M-$-41M$0.00$0.00
Net cash used for financing activities$617M-$-573M-$-478M-$-822M-$-263M
Net change in cash$1.62B$387M$1.06B$890M-$-451M
Cash at end of period$4.52B$2.89B$2.51B$1.45B$561M
Operating cash flow$1.99B$1.95B$2.1B$2.11B$1.61B
Capital expenditure-$-482M-$-401M-$-387M-$-310M-$-248M
Free cash flow$1.51B$1.55B$1.71B$1.8B$1.36B
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About GE HealthCare Technologies Inc.

        GE HealthCare Technologies Inc. is a global medical technology company that creates, manufactures, and markets a diverse range of medical devices, services, and integrated digital solutions. These offerings are designed to assist in the diagnosis, treatment, and ongoing monitoring of patients. The company boasts an extensive international presence, serving markets across the United States, Canada, Europe, the Middle East, Africa, China, Taiwan, Mongolia, and Hong Kong, among other regions. Its operations are structured across four primary business divisions: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging division specializes in advanced diagnostic imaging technologies, including systems for molecular imaging, Computed Tomography (CT) scans, Magnetic Resonance (MR) imaging, image-guided therapy, and X-ray, alongside specialized women's health products. The Ultrasound segment delivers a comprehensive suite of ultrasound solutions utilized for the screening, diagnosis, treatment, and monitoring of various diseases. These applications span radiology, primary care, women's health, cardiovascular diagnostics, point-of-care, and portable handheld devices, in addition to products supporting surgical visualization and guidance. The Patient Care Solutions segment is dedicated to providing essential medical devices, consumable products, services, and digital platforms. Its portfolio encompasses patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, and maternal-infant care products. The Pharmaceutical Diagnostics segment supplies specialized diagnostic agents to the radiology and nuclear medicine industries. These include contrast media pharmaceuticals, administered to patients prior to scans like CT, angiography, X-ray, and MR, to enhance the visibility of internal tissues and structures. It also offers molecular imaging agents, or radiopharmaceuticals – molecular tracers labeled with radioisotopes – injected into patients for advanced diagnostic imaging applications such as Single-Photon Emission Computed Tomography (SPECT), Positron Emission Tomography (PET), and specific ultrasound procedures. Established in 2022, GE HealthCare Technologies Inc. maintains its corporate headquarters in Chicago, Illinois.

        CEO
        Peter J. Arduini
        Employees
        54K
        Beta
        0.84

        Explore

        Frequently asked questions

        What is the intrinsic value of GE HealthCare Technologies Inc. (GEHC)?

        GE HealthCare Technologies Inc. (GEHC) is currently fairly valued based on the InvestorsCraft IC model — IC value is within 20% of the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is GEHC undervalued?

        GEHC trades at a price of $80.64 (Nov 21, 2026): fairly valued — IC value is within 20% of the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.